Martin Julian Abrahamson, M.B.,Ch.B.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoglycemic Agents | 24 | 2020 | 3110 | 1.620 |
Why?
|
| Diabetes Mellitus, Type 2 | 34 | 2020 | 12252 | 1.210 |
Why?
|
| Insulin | 13 | 2016 | 6610 | 0.800 |
Why?
|
| Prediabetic State | 8 | 2018 | 548 | 0.790 |
Why?
|
| Blood Glucose | 14 | 2020 | 6434 | 0.630 |
Why?
|
| Cooking | 1 | 2017 | 314 | 0.480 |
Why?
|
| Diabetes Mellitus | 7 | 2015 | 5892 | 0.430 |
Why?
|
| Insulin, Long-Acting | 4 | 2020 | 59 | 0.430 |
Why?
|
| Sulfonylurea Compounds | 1 | 2015 | 220 | 0.420 |
Why?
|
| Thiazolidinediones | 2 | 2004 | 461 | 0.360 |
Why?
|
| Health Education | 1 | 2017 | 1059 | 0.350 |
Why?
|
| Metformin | 2 | 2015 | 909 | 0.310 |
Why?
|
| Postprandial Period | 3 | 2019 | 320 | 0.270 |
Why?
|
| Algorithms | 9 | 2020 | 14199 | 0.260 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 1447 | 0.240 |
Why?
|
| Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 2004 | 30 | 0.230 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2006 | 348 | 0.220 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2020 | 475 | 0.180 |
Why?
|
| Satiation | 1 | 2019 | 84 | 0.160 |
Why?
|
| Food, Formulated | 1 | 2019 | 103 | 0.160 |
Why?
|
| Life Style | 7 | 2018 | 3931 | 0.160 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 1209 | 0.150 |
Why?
|
| Diabetic Angiopathies | 3 | 2012 | 806 | 0.150 |
Why?
|
| Hunger | 1 | 2019 | 207 | 0.150 |
Why?
|
| Self Care | 2 | 2014 | 801 | 0.140 |
Why?
|
| Anticholesteremic Agents | 1 | 2004 | 972 | 0.140 |
Why?
|
| Diabetes Complications | 2 | 2015 | 1320 | 0.140 |
Why?
|
| Diet Therapy | 1 | 2018 | 150 | 0.140 |
Why?
|
| Hypoglycemia | 3 | 2018 | 895 | 0.130 |
Why?
|
| Weight Gain | 3 | 2018 | 2359 | 0.130 |
Why?
|
| Endocrinology | 3 | 2018 | 443 | 0.130 |
Why?
|
| Women's Health | 1 | 2004 | 2081 | 0.120 |
Why?
|
| Diabetic Retinopathy | 1 | 2024 | 1299 | 0.120 |
Why?
|
| Coronary Artery Disease | 1 | 2014 | 6569 | 0.120 |
Why?
|
| Comprehensive Health Care | 1 | 2015 | 123 | 0.110 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2014 | 86 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2016 | 3447 | 0.110 |
Why?
|
| Self Efficacy | 1 | 2017 | 643 | 0.100 |
Why?
|
| Humans | 45 | 2024 | 768887 | 0.100 |
Why?
|
| Health Educators | 1 | 2011 | 19 | 0.100 |
Why?
|
| Hyperglycemia | 2 | 2015 | 1389 | 0.100 |
Why?
|
| Decision Making | 2 | 2015 | 3952 | 0.090 |
Why?
|
| Health Status | 1 | 2004 | 4095 | 0.090 |
Why?
|
| Attitude of Health Personnel | 4 | 2014 | 3925 | 0.090 |
Why?
|
| Physician-Patient Relations | 3 | 2014 | 3269 | 0.090 |
Why?
|
| Consensus | 5 | 2020 | 3214 | 0.090 |
Why?
|
| Communication Barriers | 1 | 2014 | 419 | 0.090 |
Why?
|
| Apolipoproteins B | 1 | 2012 | 386 | 0.090 |
Why?
|
| Hyperthyroxinemia | 1 | 1989 | 2 | 0.080 |
Why?
|
| Drug Combinations | 2 | 2020 | 2088 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 4862 | 0.080 |
Why?
|
| Hypertriglyceridemia | 1 | 2012 | 293 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2010 | 4042 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 10778 | 0.080 |
Why?
|
| Nutritional Status | 1 | 2017 | 1627 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2015 | 1249 | 0.080 |
Why?
|
| Medicare | 1 | 2006 | 6888 | 0.070 |
Why?
|
| Patient Preference | 1 | 2015 | 947 | 0.070 |
Why?
|
| Triiodothyronine | 1 | 1989 | 492 | 0.070 |
Why?
|
| United States | 13 | 2020 | 73180 | 0.070 |
Why?
|
| Age Factors | 3 | 2018 | 18454 | 0.070 |
Why?
|
| Formularies as Topic | 1 | 2006 | 94 | 0.060 |
Why?
|
| Thyroxine | 1 | 1989 | 665 | 0.060 |
Why?
|
| Aged | 13 | 2024 | 171790 | 0.060 |
Why?
|
| Female | 22 | 2024 | 397464 | 0.060 |
Why?
|
| Primary Health Care | 3 | 2012 | 4748 | 0.060 |
Why?
|
| Comorbidity | 2 | 2018 | 10591 | 0.060 |
Why?
|
| Patient Education as Topic | 3 | 2018 | 2339 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2010 | 1575 | 0.060 |
Why?
|
| Disease Progression | 3 | 2007 | 13677 | 0.050 |
Why?
|
| Telemedicine | 2 | 2024 | 3109 | 0.050 |
Why?
|
| Internet | 1 | 2015 | 3112 | 0.050 |
Why?
|
| Patients | 1 | 2010 | 908 | 0.050 |
Why?
|
| Glyburide | 1 | 2004 | 117 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2015 | 2192 | 0.050 |
Why?
|
| Male | 20 | 2024 | 365249 | 0.050 |
Why?
|
| Obesity | 7 | 2018 | 13087 | 0.050 |
Why?
|
| Weight Loss | 1 | 2014 | 2720 | 0.050 |
Why?
|
| Middle Aged | 16 | 2024 | 223740 | 0.050 |
Why?
|
| Carbamates | 1 | 2004 | 192 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 2402 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2015 | 2518 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 4053 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2010 | 2771 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2012 | 2701 | 0.050 |
Why?
|
| Coronary Stenosis | 1 | 2007 | 802 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2010 | 2025 | 0.050 |
Why?
|
| Exercise | 1 | 2018 | 5953 | 0.050 |
Why?
|
| Qualitative Research | 4 | 2014 | 3143 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2015 | 13054 | 0.040 |
Why?
|
| Emotions | 1 | 2012 | 2768 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2011 | 2527 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3253 | 0.040 |
Why?
|
| Sirolimus | 1 | 2007 | 1540 | 0.040 |
Why?
|
| Autoantibodies | 1 | 1989 | 2126 | 0.040 |
Why?
|
| Insulin Resistance | 2 | 2004 | 3982 | 0.040 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2019 | 41 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 2231 | 0.040 |
Why?
|
| Cholecystokinin | 1 | 2019 | 115 | 0.040 |
Why?
|
| Atherosclerosis | 1 | 2015 | 3431 | 0.040 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2003 | 465 | 0.040 |
Why?
|
| Peptide YY | 1 | 2019 | 135 | 0.040 |
Why?
|
| Adult | 12 | 2024 | 223818 | 0.040 |
Why?
|
| Voluntary Health Agencies | 1 | 2018 | 38 | 0.040 |
Why?
|
| Ghrelin | 1 | 2019 | 251 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2004 | 1351 | 0.040 |
Why?
|
| Risk Factors | 4 | 2015 | 74971 | 0.040 |
Why?
|
| Glucagon | 1 | 2019 | 534 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2004 | 1187 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2004 | 1422 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2003 | 938 | 0.030 |
Why?
|
| Triazines | 1 | 2018 | 311 | 0.030 |
Why?
|
| Stents | 1 | 2007 | 3200 | 0.030 |
Why?
|
| Piperidines | 1 | 2004 | 1669 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2013 | 4879 | 0.030 |
Why?
|
| Societies, Medical | 2 | 2018 | 3967 | 0.030 |
Why?
|
| Insulin Infusion Systems | 1 | 2016 | 221 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 417 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2006 | 1946 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 4207 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2004 | 2026 | 0.030 |
Why?
|
| Aspirin | 1 | 2006 | 3135 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 8055 | 0.030 |
Why?
|
| Denmark | 1 | 2016 | 778 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 6320 | 0.030 |
Why?
|
| Acute Disease | 1 | 2004 | 7245 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 1183 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2016 | 590 | 0.030 |
Why?
|
| Hypolipidemic Agents | 1 | 2018 | 609 | 0.030 |
Why?
|
| Retina | 1 | 2024 | 2661 | 0.030 |
Why?
|
| Cardiovascular Diseases | 5 | 2016 | 15662 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 11521 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 2108 | 0.030 |
Why?
|
| Physicians | 1 | 2011 | 4607 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 773 | 0.030 |
Why?
|
| Risk Assessment | 3 | 2014 | 24330 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2004 | 10115 | 0.020 |
Why?
|
| Europe | 1 | 2018 | 3441 | 0.020 |
Why?
|
| Leptin | 1 | 2019 | 1597 | 0.020 |
Why?
|
| Critical Illness | 1 | 2004 | 2754 | 0.020 |
Why?
|
| Decision Trees | 1 | 2013 | 509 | 0.020 |
Why?
|
| Appointments and Schedules | 1 | 2014 | 443 | 0.020 |
Why?
|
| Blood Pressure | 2 | 2016 | 8541 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 2016 | 886 | 0.020 |
Why?
|
| Counseling | 1 | 2018 | 1554 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2014 | 65485 | 0.020 |
Why?
|
| Trust | 1 | 2014 | 532 | 0.020 |
Why?
|
| Quality of Life | 2 | 2014 | 13510 | 0.020 |
Why?
|
| Thyrotoxicosis | 1 | 1989 | 85 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 1904 | 0.020 |
Why?
|
| Disease Management | 1 | 2018 | 2537 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 2280 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 10397 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 3709 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2018 | 2084 | 0.020 |
Why?
|
| Israel | 1 | 2007 | 726 | 0.020 |
Why?
|
| Fear | 1 | 2014 | 1494 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2012 | 1738 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2011 | 2437 | 0.010 |
Why?
|
| Prognosis | 1 | 2004 | 30044 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2024 | 54950 | 0.010 |
Why?
|
| Lipids | 1 | 2014 | 3345 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5323 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 2006 | 769 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2006 | 59738 | 0.010 |
Why?
|
| Sleep | 1 | 2018 | 4820 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 3233 | 0.010 |
Why?
|
| Overweight | 1 | 2013 | 2445 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7460 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 8559 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2007 | 1724 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2006 | 1600 | 0.010 |
Why?
|
| Communication | 1 | 2014 | 3908 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 1820 | 0.010 |
Why?
|
| Boston | 1 | 2011 | 9375 | 0.010 |
Why?
|
| Hypertension | 1 | 2018 | 8615 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2007 | 1459 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 2238 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1989 | 13020 | 0.010 |
Why?
|
| Sex Factors | 1 | 2006 | 10641 | 0.010 |
Why?
|
| Registries | 1 | 2007 | 8384 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 40266 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 60110 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 89247 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 39394 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2013 | 81892 | 0.000 |
Why?
|
| Animals | 1 | 2013 | 169408 | 0.000 |
Why?
|